We are live on ! Find out more

AnaptysBio

ANAB

Market cap $1.46B

48.73 USD

+0.63

1.31%

At close Updated Oct 23, 4:00 PM EDT

Pre-market

After hours

48.48

-0.25

0.51%

1 day

1.31%

5 days

2.96%

1 month

-4.02%

3 months

-11.25%

6 months

-4.95%

Year to date

8.41%

1 year

43.32%

5 years

68.03%

10 years

186.65%

About: AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Employees: 104

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 28.6%

Neutral 57.1%

Negative 14.3%

Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer

SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today announced that GSK has received U.S. Food and Drug Administration (FDA) approval for Jemperli (dostarlimab) as the first and only immunotherapy for adults with stage II and III microsatellite instability-high (MSI-H)/ mismatch repair deficient (dMMR) locally advanced rectal cancer.

Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer

Investors Business Daily

Why This IPO Stock, An AnaptysBio Spinoff, Just Skyrocketed

First Tracks Biotherapeutics posted "impressive" results for its celiac disease treatment Monday, and the IPO stock surged by double digits.

Why This IPO Stock, An AnaptysBio Spinoff, Just Skyrocketed

Zacks Investment Research

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates

AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to a loss of $1.34 per share a year ago.

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates

Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update

SAN DIEGO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today reported financial results for the second quarter and transitional fiscal year ended June 30, 2026, and provided a business update.

Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update

Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that Chris Murphy, chief financial officer, is scheduled to present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, Sept. 15, 2026. The presentation is scheduled to begin at 3:30pm ET.

Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference

Zacks Investment Research

GSK's sBLA for Jemperli Gets FDA Priority Tag in Rectal Cancer

GSK's Jemperli gets FDA priority review for dMMR/MSI-H rectal cancer with a decision due in February 2027, while Hibsago wins Japan approval in CHB.

GSK's sBLA for Jemperli Gets FDA Priority Tag in Rectal Cancer

AnaptysBio: The Royalty Waterfall Is About To Reverse

AnaptysBio is now a focused royalty management company, with its value tied primarily to Jemperli royalties from GSK. Post-spin, ANAB operates virtually with a 95% targeted EBIT margin and over $140M net cash, eliminating prior R&D burn. Jemperli royalties escalate with sales, and once the Sagard obligation is paid (expected by mid-2027), ANAB will retain high-margin, growing royalty streams.

AnaptysBio: The Royalty Waterfall Is About To Reverse

Zacks Investment Research

GSK's Jemperli Delivers Promising Interim Data in Rectal Cancer

GSK reports positive interim phase II AZUR-1 data as Jemperli meets the primary endpoint in rectal cancer, supporting potential regulatory filings.

GSK's Jemperli Delivers Promising Interim Data in Rectal Cancer

Zacks Investment Research

Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?

Here is how AnaptysBio, Inc. (ANAB) and Electromed, Inc. (ELMD) have performed compared to their sector so far this year.

Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?

Zacks Investment Research

Wall Street Analysts See a 38.75% Upside in AnaptysBio (ANAB): Can the Stock Really Move This High?

The consensus price target hints at a 38.8% upside potential for AnaptysBio (ANAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 38.75% Upside in AnaptysBio (ANAB): Can the Stock Really Move This High?

See News Rankings

Price charts implemented using Lightweight Charts™